Effects of L-2-oxothiazolidine-4-carboxylate on the cytotoxic activity and toxicity of cyclophosphamide in mice bearing B16F10 melanoma liver metastases.
Glutathione (GSH) is the major non-protein thiol in cells that plays a critical role against damage from electrophilic agents such as alkylating drugs. Selective therapeutic GSH elevation in normal but not in tumour cells has been suggested as a means of protecting host tissues against more intense doses of chemotherapy. The present study investigated the response of B16 melanoma to treatment with the cysteine pro-drug L-2-oxothiazolidine-4-carboxylate (OTZ), alone and in combination with cyclophosphamide (CY). We found that OTZ decreased the GSH levels and proliferation rate of B16 melanoma cells in vitro, sensitizing them to the cytotoxic action of the activated metabolite of CY, acrolein (AC). In contrast to OTZ, the cysteine deliverer N-acetylcysteine (NAC) enhanced B16 melanoma cell proliferation by increasing GSH levels, and markedly decreased the sensitivity of these tumour cells to AC. In vivo studies showed the antitumoral activity of OTZ in B16 melanoma liver metastasis-induced mice, increasing their life span. We also observed that, whereas with CY treatment the GSH levels in peripheral blood mononuclear cells (PBMCs) were reduced and a dose-dependent leukopenia was produced, OTZ significantly increased PBMC GSH content, reducing toxicity and enhancing the survival of mice bearing established melanoma liver metastases treated with lethal dose CY. These results suggest a critical role for OTZ in protecting against alkylator agent-induced immunosuppression, which may allow the dose escalation of these cytostatic drugs to improve their therapeutic benefit in the treatment of malignant melanoma.
del Olmo
M
M
Department of Surgery, School of Medicine and Dentistry, University of the Basque Country, Vizcaya, Spain.
Alonso-Varona
A
A
Castro
B
B
Calle
Y
Y
Bilbao
P
P
Palomares
T
T
D000171:Acrolein / Q000493:pharmacokinetics / Q000633:toxicity; D000478:Alkylation / Q000187:drug effects; D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000493:pharmacokinetics / Q000633:toxicity*; D001711:Biotransformation; D002455:Cell Division / Q000187:drug effects; D003520:Cyclophosphamide / Q000493:pharmacokinetics / Q000633:toxicity*; D003545:Cysteine / Q000493:pharmacokinetics; D018450:Disease Progression; D004347:Drug Interactions; D004354:Drug Screening Assays, Antitumor; D005260:Female; D005978:Glutathione / Q000378:metabolism; D007970:Leukopenia / Q000139:chemically induced / Q000517:prevention & control*; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary*; D008546:Melanoma, Experimental / Q000188:drug therapy / Q000556:secondary*; D051379:Mice; D008810:Mice, Inbred C57BL; D010084:Oxidation-Reduction; D011355:Prodrugs / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011761:Pyrrolidonecarboxylic Acid; D013844:Thiazoles / Q000493:pharmacokinetics / Q000627:therapeutic use*; D053778:Thiazolidines
D018906:Antineoplastic Agents, Alkylating; D011355:Prodrugs; D013844:Thiazoles; D053778:Thiazolidines; D000171:Acrolein; D003520:Cyclophosphamide; D005978:Glutathione; D003545:Cysteine; D011761:Pyrrolidonecarboxylic Acid; C029536:2-oxothiazolidine-4-carboxylic acid